US Patent 8,602,215 (Dronedarone plus beta-blocker interaction risk management): What is actually claimed and where it sits in the US patent landscape
What does US 8,602,215 claim, in enforceable scope terms?
US Patent 8,602,215 claims a clinical method for reducing cardiovascular hospitalization risk and managing the dronedarone/beta-blocker interaction in a patient with paroxysmal or persistent AF or AFL who has a recent AF/AFL episode and cardiovascular risk factors, where the patient is either in sinus rhythm or will be cardioverted.
The claim set is built around three locked-in treatment mechanics:
-
Dronedarone administration first
- Administer dronedarone or a pharmaceutically acceptable salt.
-
Then low-dose beta-blocker initiation
- Start a beta-blocker at a low dose.
-
Then an ECG-gated titration
- Perform an ECG assessment after low-dose initiation.
- Increase the beta-blocker dose only if the ECG results show good tolerability.
This creates a “sequence + condition” method profile: (dronedarone) then (low-dose beta-blocker) then (ECG) then (titrate only if tolerable). That structure matters for both direct infringement (who must do what, in what order) and for design-around (changing sequencing, abandoning ECG gating, or using different tolerability criteria).
Claim 1 is the core; dependent claims lock dose, salt, specific beta-blockers, and objective tolerability rules
Claim 1 (independent) defines:
- Patient population
- Paroxysmal or persistent AF/AFL
- Recent episode and associated cardiovascular risk factors
- In sinus rhythm or being cardioverted
- Therapeutic goal
- “Reduce the risk of cardiovascular hospitalization”
- Treatment method
- Administer dronedarone (or salt)
- Initiate beta-blocker at low dose
- ECG assessment
- Increase beta-blocker dose only if ECG results confirm “good tolerability”
Dependent claims 2-16 add specific boundaries that narrow or specify implementation:
Dose and salt specifics
- Claim 2: Dronedarone 400 mg twice daily with meals
- Claim 3: Dronedarone salt is hydrochloride
Beta-blocker titration boundary
- Claim 4: Beta-blocker dose can be increased up to “a fraction of the recommended dose higher than the low dose”
- This is a relative limiter; it does not define a fixed mg cap in the text provided.
Choice of beta-blocker
- Claim 5: Beta-blocker is metoprolol
- Claim 8: Beta-blocker is propranolol
Metoprolol low-dose range
- Claim 6: Low dose of metoprolol is less than 200 mg
- Claim 7: Low dose of metoprolol is 100 mg
Propranolol low-dose range
- Claim 9: Low dose of propranolol is less than 160 mg
- Claim 10: Low dose of propranolol is 40 mg
“Good tolerability” objective tolerability criteria
- Claim 11: Good tolerability indicated by heart rate > 50 bpm
- Claim 12: Good tolerability indicated by PR-interval < 200 ms
Cardiovascular risk factor definitions
- Claim 13: Patient has at least one risk factor selected from:
- age > 70
- hypertension
- diabetes
- prior cerebrovascular accident
- left atrial diameter ≥ 50 mm
- left ventricular ejection fraction < 40%
- Claim 14: Risk factor includes hypertension
- Claim 15: Risk factor includes diabetes
Recency window
- Claim 16: AF/AFL episode was within the last 6 months
Practical enforceability note: because the claims are methods of medical treatment with objective ECG/physiology-based gating (HR and PR), an accused workflow must match those steps. If a clinician instead uses a non-ECG metric, or titrates without that ECG-based “good tolerability” condition, the method claim narrows sharply.
How broad is Claim 1 vs how narrow are the dependent claims?
Claim 1 breadth
- Broadest element is the method scaffold:
- dronedarone + low-dose beta-blocker + ECG assessment + conditional titration
- It is narrowed by:
- AF/AFL subtype (paroxysmal/persistent)
- “recent episode”
- sinus rhythm or planned cardioversion
- “associated cardiovascular risk factors”
- It does not restrict the beta-blocker molecule in the independent claim as provided, but dependent claims do.
Dependent claims narrow scope by hard constraints
- Drug product specificity: dronedarone 400 mg BID with meals and hydrochloride salt (claims 2-3)
- Exact beta-blocker examples: metoprolol or propranolol (claims 5 and 8)
- Exact dose examples: metoprolol 100 mg (claim 7) and propranolol 40 mg (claim 10)
- Hard tolerability criteria: HR > 50 bpm and PR < 200 ms (claims 11-12)
- Patient feature examples: hypertension or diabetes (claims 14-15) plus a risk factor set (claim 13)
- Recency: AF/AFL within 6 months (claim 16)
A useful way to frame enforceable coverage:
- To capture claim 1, infringement can be satisfied by meeting the patient + sequence + ECG-gated titration logic.
- To capture claims 2, 3, 7, 10, 11, 12, 14-16, an accused method would need to match those exact implementation boundaries.
What do the claim mechanics imply for design-around strategies?
Based on the claim wording provided, the key infringement “hooks” are:
- Sequence: dronedarone administered before beta-blocker initiation
- ECG assessment: performed as part of the titration decision
- Conditionality: beta-blocker dose increase only if ECG verifies “good tolerability”
- Objective tolerability definitions: at least in dependent claims, HR and PR thresholds
Design-around vectors that directly attack those hooks (conceptually) include:
- Changing the workflow so that beta-blocker titration occurs without an ECG assessment used for the “only if” decision
- Using a different tolerability gate that does not rely on PR interval/heart-rate thresholds as defined in dependent claims
- Altering dose sequence (e.g., beta-blocker first, then dronedarone) to break “administer dronedarone … and then perform steps a-c”
- Treating a patient population that does not satisfy the “associated cardiovascular risk factors” definition in claim 13 or does not meet the “recent episode” requirement as constrained by claim 16
This is not an opinion on clinical appropriateness; it is a claim-structure mapping.
US patent landscape: how this claim family type tends to interact with prior art and concurrent filings
What technical/clinical patent theme does 8,602,215 align to?
The patent sits in the intersection of:
- rhythm control therapy (dronedarone) for AF/AFL
- rate control adjunct (beta-blockers) despite known interaction risk
- a risk management protocol using ECG-based tolerability gating to guide titration
In patent-land terms, the likely competitive and citation context falls into three lanes:
- Dronedarone composition/use patents (method-of-use for AF/AFL, dosage regimens)
- Beta-blocker use and titration protocols (rate control, dose management)
- Combination therapy management addressing safety and tolerability, often framed as “titration,” “monitoring,” or “dose adjustment based on ECG parameters.”
Within that structure, US 8,602,215’s distinguishing element is the combination of:
- patient profile (recent AF/AFL episode + risk factors, sinus rhythm or cardioversion)
- sequencing of dronedarone followed by beta-blocker low-dose initiation
- ECG assessment used as the gate for titration decisions
Claim chart style breakdown (what elements an accused protocol must have)
Below is a tight element mapping for claim 1 as provided, plus the most operational dependent limitations.
Claim 1 elements (method of managing interaction risk)
| Element |
Requirement from Claim 1 |
| Patient |
Paroxysmal or persistent AF/AFL with recent episode and cardiovascular risk factors |
| State of patient |
In sinus rhythm or cardioverted |
| Intervention 1 |
Administer dronedarone (or pharmaceutically acceptable salt) |
| Intervention 2 |
Initiate beta-blocker at a low dose |
| Assessment |
Perform ECG assessment |
| Conditional decision |
Increase beta-blocker dose only if step b ECG results verify good tolerability |
Most operational dependent claim elements
| Dependent claim |
Added limitation |
| Claim 2 |
Dronedarone 400 mg twice daily with meals |
| Claim 3 |
Salt is hydrochloride |
| Claim 5-7 |
Metoprolol low dose <200 mg, with example 100 mg |
| Claim 8-10 |
Propranolol low dose <160 mg, with example 40 mg |
| Claim 11-12 |
HR >50 bpm and/or PR <200 ms as good tolerability indicators |
| Claim 13 |
Risk factors list includes age >70, HTN, diabetes, prior CVA, LAD ≥50 mm, LVEF <40% |
| Claim 14-15 |
Hypertension and/or diabetes |
| Claim 16 |
AF/AFL episode within 6 months |
Scope implications for investors and licensing: what parts are likely to drive value
1) Breadth of claim 1 vs enforceability risk
The claim 1 scaffold is clinically plausible and programmatically actionable. Enforceability tends to be stronger when:
- the method is specific enough to define concrete steps (it is)
- “good tolerability” is objective (dependent claims 11-12 do)
- patient criteria and timing are defined (claim 16, claim 13)
The value risk tends to be higher when:
- “recent episode” and “associated cardiovascular risk factors” are interpreted broadly or when ECG-based decision-making could be done for other reasons
- “good tolerability” in claim 1 is not fully quantified unless you rely on dependent claim thresholds
What this means in practice: the monetizable core usually sits in the dependent claims with explicit HR/PR thresholds and dosing examples, because they reduce ambiguity in infringement analysis.
2) Competitive positioning
Any other US filings targeting:
- dronedarone + beta-blocker combination management
- ECG monitoring-based titration rules
- dosing low-dose then titration logic
would tend to overlap most with the same patient-state scaffold and monitoring gate.
To map competitive threats, the critical question is whether other patents claim:
- similar ECG parameters
- similar HR/PR thresholds
- similar sequencing rules
- or similar dosing regimes
Without the full USPTO family for this patent, the landscape cannot be quantified in a data-driven way here. The claim content provided already makes clear the technical overlap zones that other filings would need to address or avoid.
Key Takeaways
- US 8,602,215 claims a dronedarone-first protocol that initiates a beta-blocker at low dose, then uses an ECG assessment to decide whether to titrate up based on “good tolerability.”
- Dependent claims narrow scope with specific dronedarone dosing (400 mg twice daily with meals), hydrochloride salt, specific beta-blockers (metoprolol and propranolol), example low doses (100 mg metoprolol; 40 mg propranolol), and objective tolerability markers (HR >50 bpm; PR <200 ms).
- Patient selection is not generic: claims require paroxysmal or persistent AF/AFL, a recent episode and at least one cardiovascular risk factor (including age >70, hypertension, diabetes, prior CVA, LAD ≥50 mm, LVEF <40%) and, in the recency-dependent claim, AF/AFL within 6 months.
FAQs
1) Does claim 1 require a specific beta-blocker drug in the independent claim?
No; claim 1 as provided requires administering “a beta-blocker treatment,” and specific beta-blockers appear in dependent claims (metoprolol and propranolol).
2) Are HR and PR thresholds required to practice claim 1?
Claim 1 uses the concept of “good tolerability” verified by ECG results. The explicit HR >50 bpm and PR <200 ms tolerability thresholds appear in dependent claims.
3) Is ECG assessment mandatory for infringement?
Yes. Claim 1 requires performing an ECG assessment and using those results to determine whether beta-blocker dose can be increased.
4) Does the patent require cardioversion or sinus rhythm?
Claim 1 requires the patient be in sinus rhythm or will be cardioverted.
5) What dose examples tighten dependent claim coverage?
The text provided includes example low doses of metoprolol 100 mg and propranolol 40 mg, plus dronedarone 400 mg twice daily with meals.
References
[1] US Patent 8,602,215, claims as provided in the prompt.
